Oral liquids · Contract manufacturing in India

Cefdinir 250 mg / 5 ml · Oral suspension

Discuss third-party manufacturing of Cefdinir 250 mg / 5 ml Oral suspension with Walter Healthcare, India. Share your target market, required bottle count and finished volume, packaging and launch timeline for a product-specific quotation.

Catalogue reference: WH-5978
Composition and strength: Cefdinir 250 mg / 5 ml
Dosage form: Oral suspension
Indicative administration route: Oral
Therapeutic navigation area: Anti-infectives
Pharmacological class: Cephalosporin antibiotic
Manufacturing stream: Beta-lactam

Catalogue details support an initial B2B discussion. Walter confirms the applicable unit, current licence scope, formula, target market and commercial feasibility before making a commitment.

Clinical reference

Mechanism and pharmacokinetics.

Explore the published evidence for the ingredients in Cefdinir 250 mg / 5 ml Oral suspension. Each reference identifies its source formulation and study context. Ingredient studies describe the named reference product; they do not establish the pharmacokinetics, clinical suitability or bioequivalence of this finished formulation.

How to read our product information and sources ↗

Prescribing-label excerpts

Cefdinir

Reference for: Cefdinir. Source presentation: powder, for suspension. Source route: oral.

The source label presents its clinical-pharmacology findings together. These selected passages retain the source’s study context; the full label provides the complete discussion.

Clinical pharmacology

Mechanism of Action — As with other cephalosporins, bactericidal activity of cefdinir results from inhibition of cell wall synthesis. Cefdinir is stable in the presence of some, but not all, β-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins are susceptible to cefdinir.

Mechanism of Resistance — Resistance to cefdinir is primarily through hydrolysis by some β-lactamases, alteration of penicillin-binding proteins (PBPs) and decreased permeability. Cefdinir is inactive against most strains of Enterobacterspp., Pseudomonasspp., Enterococcusspp., penicillin-resistant streptococci, and methicillin-resistant staphylococci. β-lactamase negative, ampicillin-resistant (BLNAR) H. influenzaestrains are typically non-susceptible to cefdinir.

Antimicrobial Activity — Cefdinir has been shown to be active against most strains of the following microorganisms, both in vitroand in clinical infections as described in INDICATIONS AND USAGE .

Selected passages from the cited U.S. prescribing label. The studies concern the source product and populations named in each passage; they do not establish Walter-product bioequivalence, an approved indication, or the kinetics of another fixed combination. Tables and the full prescribing information remain available in the source.

Source: DailyMed: Cefdinir — powder, for suspension

Reference accessed 2026-10-06. Label revision: 2026-09-01.

Manufacturing & packaging brief

Plan the oral-suspension presentation.

Use this preparation guide for Cefdinir 250 mg / 5 ml Oral suspension. These are the decisions to resolve with the technical team before a site, process and commercial scope are confirmed.

Presentation & formulation

Clarify whether the requirement is a ready-to-use suspension or a powder for reconstitution. Provide concentration, final volume and formula details for the requested presentation.

Quality & technical transfer

Request review of the applicable suspension specification, analytical methods and measuring accuracy. Reconstitution and in-use statements need their own supporting evidence where relevant.

Review the technical documents

Packaging configuration

Specify bottle capacity, fill or reconstitution volume, closure and measuring device. List any diluent or accessory separately in the brief.

Explore packaging options

Details to confirm for this record

Concentration and pack size: The record includes a concentration or percentage expression. Confirm its complete basis, then specify the finished fill volume or weight separately. Do not treat pack size as the strength.
Manufacturing stream: The catalogue assigns this record to the beta-lactam stream. Request review of the proposed unit, product-family scope and applicable segregation arrangements before selecting a manufacturing site.

Quantities, MOQ & lead time

For Cefdinir 250 mg / 5 ml Oral suspension, state the bottle count and finished volume, target market and reorder forecast. MOQ and lead time depend on the assessed formula, process, components, testing and project readiness; request those terms in writing.

Discuss this manufacturing brief

Explore the context

Build the right manufacturing brief.

Dosage-form capabilitiesOral liquids Therapeutic navigationAnti-infectives Full catalogueSearch other compositions

Common questions

Before you request a quotation.

Cefdinir 250 mg / 5 ml Oral suspension

What is listed in the catalogue?

The catalogue lists Cefdinir 250 mg / 5 ml as oral suspension in its anti-infectives navigation area and beta-lactam manufacturing stream.

How do you confirm manufacturing availability?

Send Walter your requirement for Cefdinir 250 mg / 5 ml Oral suspension. The team reviews the applicable product permission and unit, formulation and equipment fit, testing, packaging and production schedule before confirming the manufacturing scope in writing. Request the relevant product and facility documents with your enquiry.

What do I need for a quotation?

Share the exact composition and strength, oral suspension presentation, target market, initial quantity, preferred pack and timing. Identify whether this is a new product, development brief or transfer.

The quotation must confirm MOQ, inclusions, prerequisites and lead time for the proposed product and site.

What is needed for Indian and export markets?

For India, share the intended brand or institutional supply requirement, pack sizes, initial order quantity and artwork needs for Cefdinir 250 mg / 5 ml Oral suspension. Confirm the applicable product permission, manufacturing unit and labelling requirements with the team.

For export, identify each destination country, proposed pack, language and registration or dossier requirements. Ask which product-specific quality and stability documents are available. Container compatibility and destination-market requirements need review; a catalogue record does not establish export registration or a shelf-life commitment.

How do I submit my enquiry?

Use the product-specific enquiry button to carry this composition and dosage form into the form. After a successful submission, a receipt reference confirms that your brief has been saved for review. Use the RFQ checklist to prepare the remaining details.

Technical document review

Which documents can I ask Walter to review?

Ask about manufacturing and packing records, specifications, analytical methods, Certificates of Analysis (COA), stability evidence, the Process Validation Protocol (PVP) and Process Validation Report (PVR). The wider checklist below covers supplier qualification, technical transfer and ongoing supply.

View the full document checklist 14 review areas

Site, licence and audit scope: Manufacturing licence, applicable product permissions, GMP certificates, Site Master File, supplier-qualification questionnaire and relevant audit responses.
Manufacturing, packing and batch release: Master Formula Record (MFR), master packing instructions, Batch Manufacturing Record (BMR), Batch Packing Record (BPR), reconciliation and authorised release records.
Process validation and continued verification: Process Validation Protocol (PVP), Process Validation Report (PVR), process performance qualification documents and continued process verification trends.
Equipment, facilities and utilities: Validation Master Plan (VMP), user requirements, DQ/IQ/OQ/PQ records, calibration and maintenance evidence for relevant equipment and utilities.
Cleaning, carryover and hold times: Cleaning Validation Protocol (CVP), Cleaning Validation Report (CVR), residue limits, recovery studies and applicable clean, dirty and process hold-time studies.
Specifications and analytical evidence: Specifications, Method of Analysis (MOA), Standard Testing Procedure (STP), Certificates of Analysis (COA), analytical validation, verification and method-transfer records.
Stability, packaging and transport: Stability protocols/reports, ongoing stability commitments, pack specifications, approved artwork, compatibility and applicable packaging or transport studies.
Development and technology transfer: Development report, technology-transfer protocol/report, gap assessment, control strategy, critical quality attributes and critical process parameters.
Quality reviews, investigations and changes: Product Quality Review (PQR) / Annual Product Review (APR), deviations, CAPA, change control, OOS/OOT trends, complaints, recalls and relevant SOP/training records.
Material suppliers and impurity risks: API/excipient supplier qualification, traceability, material COAs, relevant origin declarations and impurity risk assessments with supporting tests.
Sterile-product evidence, where applicable: Contamination Control Strategy (CCS), media-fill/aseptic simulation reports, sterilisation and filtration validation, environmental monitoring, sterility/endotoxin and container-closure integrity evidence.
Computerised systems and data integrity: Computerised-system validation, access controls, audit-trail review, backup/restore checks and relevant data-integrity procedures.
Market-specific regulatory support: Applicable dossier sections, API master-file/CEP support, bioequivalence or biowaiver evidence and Certificate of a Pharmaceutical Product (CPP/CoPP), where required and available.
Quality agreement and access arrangements: Quality/technical agreement covering responsibilities, release, changes, subcontracting, investigations, complaints, recalls, audits and document access.

Agree the list for the exact product, site, process, pack, market and project stage. QA confirms what exists, applies and may be shared; some records may require an NDA, redaction or controlled review. See document definitions and review guidance.

Important qualification

This B2B catalogue record is not proof of current approval or confirmation that Cefdinir 250 mg / 5 ml Oral suspension is available for sale. It is not prescribing information or patient advice. Any Drugs Rules status, current approval, exemption, applicable unit, licence scope, formulation, claims, brand use, destination-market registration and commercial feasibility require documentary verification and Walter's written confirmation. Read the full regulatory disclaimer.

Composition and classification are taken from Walter's product catalogue. The manufacturing guide helps buyers prepare a technical brief. Clinical references, where shown, describe the cited product and study. Manufacturing guide updated 8 October 2026.